Relationship between ustekinumab trough concentrations and both clinical and biological remission in patients with Crohn's disease

Lao Domínguez, Francisco Ángel; Fobelo Lozano, María José; Gutiérrez Pizarraya, Antonio; Castro Fernández, Manuel

doi:10.1016/j.gastrohep.2022.10.016

array:23 ["pii" => "S021057052200262X" "issn" => "02105705" "doi" => "10.1016/j.gastrohep.2022.10.016" "estado" => "S300" "fechaPublicacion" => "2023-10-01" "aid" => "2009" "copyright" => "Elsevier España, S.L.U.. All rights reserved" "copyrightAnyo" => "2022" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Gastroenterol Hepatol. 2023;46:631-2" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "itemSiguiente" => array:18 [ "pii" => "S021057052200276X" "issn" => "02105705" "doi" => "10.1016/j.gastrohep.2022.11.004" "estado" => "S300" "fechaPublicacion" => "2023-10-01" "aid" => "2020" "copyright" => "Elsevier España, S.L.U." "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Gastroenterol Hepatol. 2023;46:633-4" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "Image of the month" "titulo" => "Spontaneous cutaneous fistula secondary to hepatic hydatidosis" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "633" "paginaFinal" => "634" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Fístula cutánea secundaria a hidatidosis hepática" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1173 "Ancho" => 2508 "Tamanyo" => 356776 ] ] "descripcion" => array:1 [ "en" => "Cutaneous fistula (arrow) in the right upper quadrant of the abdominal wall (A) with draining grape-like bodies (B)." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Miguel Sogbe, José Luis del Pozo" "autores" => array:2 [ 0 => array:2 [ "nombre" => "Miguel" "apellidos" => "Sogbe" ] 1 => array:2 [ "nombre" => "José Luis" "apellidos" => "del Pozo" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S021057052200276X?idApp=UINPBA00004N" "url" => "/02105705/0000004600000008/v1_202309280830/S021057052200276X/v1_202309280830/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S0210570522002096" "issn" => "02105705" "doi" => "10.1016/j.gastrohep.2022.08.005" "estado" => "S300" "fechaPublicacion" => "2023-10-01" "aid" => "1977" "copyright" => "Elsevier España, S.L.U." "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Gastroenterol Hepatol. 2023;46:629-30" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "es" => array:11 [ "idiomaDefecto" => true "cabecera" => "Carta científica" "titulo" => "Tofacitinib para el tratamiento de la afección inflamatoria del reservorio refractaria a infliximab" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "629" "paginaFinal" => "630" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Tofacitinib for the treatment of inflammatory condition of the ileoanal pouch refractory to infliximab" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figura 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1611 "Ancho" => 2925 "Tamanyo" => 227964 ] ] "descripcion" => array:1 [ "es" => "Evolución de los valores de hemoglobina (g/dl) en los dos últimos años (enero 2020-mayo-2022)." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Marta Fortuny, Laura Gutiérrez-Rios, Eva Vayreda, Míriam Mañosa, Eugeni Domènech" "autores" => array:5 [ 0 => array:2 [ "nombre" => "Marta" "apellidos" => "Fortuny" ] 1 => array:2 [ "nombre" => "Laura" "apellidos" => "Gutiérrez-Rios" ] 2 => array:2 [ "nombre" => "Eva" "apellidos" => "Vayreda" ] 3 => array:2 [ "nombre" => "Míriam" "apellidos" => "Mañosa" ] 4 => array:2 [ "nombre" => "Eugeni" "apellidos" => "Domènech" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2444382423001268" "doi" => "10.1016/j.gastre.2023.07.002" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2444382423001268?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0210570522002096?idApp=UINPBA00004N" "url" => "/02105705/0000004600000008/v1_202309280830/S0210570522002096/v1_202309280830/es/main.assets" ] "en" => array:14 [ "idiomaDefecto" => true "cabecera" => "Scientific letter" "titulo" => "Relationship between ustekinumab trough concentrations and both clinical and biological remission in patients with Crohn's disease" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "631" "paginaFinal" => "632" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Francisco Ángel Lao Domínguez, María José Fobelo Lozano, Antonio Gutiérrez Pizarraya, Manuel Castro Fernández" "autores" => array:4 [ 0 => array:4 [ "nombre" => "Francisco Ángel" "apellidos" => "Lao Domínguez" "email" => array:1 [ 0 => "fralaodom@gmail.com" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "*" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "María José" "apellidos" => "Fobelo Lozano" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] ] ] 2 => array:3 [ "nombre" => "Antonio" "apellidos" => "Gutiérrez Pizarraya" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] ] ] 3 => array:3 [ "nombre" => "Manuel" "apellidos" => "Castro Fernández" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "b" "identificador" => "aff0010" ] ] ] ] "afiliaciones" => array:2 [ 0 => array:3 [ "entidad" => "Hospital Universitario Virgen de Valme, Pharmacy Service, Seville, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Hospital Universitario Virgen de Valme, Digestive Medicine Service, Seville, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Relación entre las concentraciones mínimas de ustekinumab y la remisión clínica y biológica en pacientes con enfermedad de Crohn" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1984 "Ancho" => 3175 "Tamanyo" => 220387 ] ] "descripcion" => array:1 [ "en" => "A. Quartile distribution of ustekinumab levels according clinical remission. B. Ustekinumab levels according clinical remission. C. Ustekinumab levels according biological remission. D. Ustekinumab levels according clinical remission in patients without intestinal resection surgery. NS: not significant." ] ] ] "textoCompleto" => "The data about TDM of ustekinumab is still limited despite being a potential drug for it.<a class="elsevierStyleCrossRefs" href="#bib0025">1–4</a> Taking into consideration the potential benefits of TDM, the addition of ustekinumab monitoring to clinical practice could improve clinical decisions in the treatment of Crohn disease (CD) for which it is necessary to provide more data in this regard.We studied patients with CD undergoing maintenance treatment with ustekinumab who underwent at least one determination of serum ustekinumab level to provide further evidence of the correlation between them and both clinical and biological remission.All samples were classified according to disease activity at the time of level determination. Clinical remission was established through Harvey-Bradshaw index considering no disease activity when it had a value ≤4. Biological remission was based on analytical values of both CRP (<5mg/L) and CAL (<250μg/g). Sample extraction was performed just before the next administration of ustekinumab.Forty one samples from thirty seven patients were collected. Median age was 43 years (IQR: 35–52.5) and 20 patients were women. CD was located in 62.2% (N=23) in ileum-colon, 27% (N=10) in ileum and 10.8% (N=4) in colon. The profile of CD was inflammatory in 43.2%, stenosing in 32.4%, penetrating in 10.8% and stenosing-penetrating in 13.5%. Intestinal resection surgery prior to the onset of ustekinumab was present in 45.9% of the patients. In this group of patients, surgery was performed at least 1 year before its inclusion in the study.Ustekinumab was used as the third line of biological treatment in 70.3% of patients, 27% in the second and 10.3% in the fourth. The dosing regimen at the time of sample extraction was 90mg every 8 weeks (68.3%), every 7 weeks (4.9%), every 6 weeks (9.8%) and every 4 weeks (17.1%). The median treatment time was 23 months (IQR: 10–29). Eight patients (10.3%) were reinduced with an IV dose with a median time between ustekinumab reinduction and sample extraction of 34.6 weeks (IQR: 22.8–38.6). 5.4% of patients were on concomitant immunomodulatory treatment (methotrexate). Albumin serum median level was 4.47g/dL (IQR: 4.23–4.85).Trough serum concentration was determined in all patients in the maintenance phase (median of 23 months [IQR: 10-29]). No antibodies (ADA) against ustekinumab were detected in any patient. In general, there was an increasing trend in the percentage of patients in clinical remission as the serum drug level increased (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>A). In samples from patients with clinical remission, median minimum serum ustekinumab concentrations were 2.78 (IQR: 1.84–4.13)μg/mL; in the remaining samples without clinical remission the level was 2.08 (IQR: 1.05–3.5)μg/mL (p=0.337) (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>B). The CAL level was available in 68.3% of patients. In patients with biological remission, median CAL and CRP values were 116.7μg/g (IQR: 71.8–213.9) and 1.9mg/L (IQR: 1.3–3.1) respectively. In patients without remission the values were 206.4μg/g (IQR: 64.5–378.1) (p=0.595) and 3.9mg/L (IQR: 1.85–12.3) (p<0.05) respectively. Ustekinumab serum level of patients seems to be higher in those with both clinical and biological remission which is consistent with published results on literature, however these differences were statistically non-significant probably due to the low sample size (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>B and C). On the other hand, range of ustekinumab levels as quartiles has to be interpreted with caution (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>A), since the possible optimal interval to achieve clinical remission is expected to be very small when ustekinumab is administered subcutaneously and with a long period between doses.<elsevierMultimedia ident="fig0005"></elsevierMultimedia>It must be taken into account that in clinical practice conditions, the population is very heterogeneous, with different affected sites, previous lines of treatment, with or without previous surgery. Therefore, the results obtained were also analyzed by dividing them into two groups of patients, with or without intestinal resection surgery prior to ustekinumab. In patients without intestinal resection in clinical remission showed a significant higher in median trough serum drug concentrations compared to patients without clinical remission (2.77 [IQR: 2.01–4.45] vs. 1.67 [IQR: 0.58–2.06]μg/mL; p=0.005) (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>D).In conclusion, our study suggests that in CD patients without intestinal resection surgery ustekinumab serum levels may be related to clinical remission, being higher in those with clinical remission. Regarding all CD patients, ustekinumab serum levels seems to be higher in those with clinical and biological remission, but these differences did not have a statistical significance.FundingThis research has not received specific support from public sector agencies, commercial sector or non-profit entities." "textoCompletoSecciones" => array:1 [ "secciones" => array:2 [ 0 => array:2 [ "identificador" => "sec0005" "titulo" => "Funding" ] 1 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "multimedia" => array:1 [ 0 => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1984 "Ancho" => 3175 "Tamanyo" => 220387 ] ] "descripcion" => array:1 [ "en" => "A. Quartile distribution of ustekinumab levels according clinical remission. B. Ustekinumab levels according clinical remission. C. Ustekinumab levels according biological remission. D. Ustekinumab levels according clinical remission in patients without intestinal resection surgery. NS: not significant." ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:4 [ 0 => array:3 [ "identificador" => "bib0025" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A comprehensive literature review and expert consensus statement on therapeutic drug monitoring of biologics in inflammatory bowel disease" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A.S. Cheifetz" 1 => "M.T. Abreu" 2 => "W. Afif" 3 => "R.K. Cross" 4 => "M.C. Dubinsky" 5 => "E.V. Loftus" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.14309/ajg.0000000000001396" "Revista" => array:6 [ "tituloSerie" => "Am J Gastroenterol" "fecha" => "2021" "volumen" => "116" "paginaInicial" => "2014" "paginaFinal" => "2025" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34388143" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0030" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Update on TDM (therapeutic drug monitoring) with ustekinumab, vedolizumab and tofacitinib in inflammatory bowel disease" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "S. Restellini" 1 => "W. Afif" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3390/jcm10061242" "Revista" => array:4 [ "tituloSerie" => "J Clin Med" "fecha" => "2021" "volumen" => "10" "paginaInicial" => "1242" ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0035" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pharmacokinetics and exposure response relationships of ustekinumab in patients with Crohn's disease" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "O.J. Adedokun" 1 => "Z. Xu" 2 => "C. Gasink" 3 => "D. Jacobstein" 4 => "P. Szapary" 5 => "J. Johanns" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1053/j.gastro.2018.01.043" "Revista" => array:6 [ "tituloSerie" => "Gastroenterology" "fecha" => "2018" "volumen" => "154" "paginaInicial" => "1660" "paginaFinal" => "1671" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29409871" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0040" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Monitoring vedolizumab and ustekinumab drug levels in patients with inflammatory bowel disease: hype or hope?" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "D. Alsoud" 1 => "S. Vermeire" 2 => "B. Verstockt" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.coph.2020.09.002" "Revista" => array:5 [ "tituloSerie" => "Curr Opin Pharmacol" "fecha" => "2020" "volumen" => "55" "paginaInicial" => "17" "paginaFinal" => "30" ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/02105705/0000004600000008/v1_202309280830/S021057052200262X/v1_202309280830/en/main.assets" "Apartado" => array:4 [ "identificador" => "9030" "tipo" => "SECCION" "es" => array:2 [ "titulo" => "Cartas científicas" "idiomaDefecto" => true ] "idiomaDefecto" => "es" ] "PDF" => "https://static.elsevier.es/multimedia/02105705/0000004600000008/v1_202309280830/S021057052200262X/v1_202309280830/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S021057052200262X?idApp=UINPBA00004N"]

ISSN: 0210-5705

La misión de Gastroenterología y Hepatología es dar cobertura a una amplia gama de temas relacionados con la gastroenterología y hepatología, incluidos los avances más recientes en la patología del tubo digestivo, enfermedad inflamatoria intestinal, hígado, páncreas y vías biliares, siendo una herramienta indispensable para gastroenterólogos, hepatólogos, cirujanos, internistas y médicos generalistas, ofreciendo revisiones exhaustivas y actualizaciones de temas relacionados con la especialidad.

Además de los manuscritos con revisión científica externa sistemática, rigurosamente seleccionados, que se publican en las secciones de investigación (artículos de investigación, cartas científicas, editoriales y cartas al director), la revista también publica guías clínicas y documentos de consenso de las principales sociedades científicas. Es la revista oficial de la Asociación Española de Gastroenterología (AEG), de la Asociación Española para el Estudio del Hígado (AEEH), del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) y de la Sociedad Española de Enfermedad Celíaca (CEEC). La publicación está incluida en Medline/Pubmed, en el Science Citation Index Expanded, y en SCOPUS.

Ver más Opción Open Access

Indexada en:

SCIE/Journal of Citation Reports, Index Medicus/Medline, Excerpta Medica/EMBASE, SCOPUS, CANCERLIT, IBECS

Artículo

Opciones para acceder a los textos completos de la publicación Gastroenterología y Hepatología

Suscriptor

Suscriptor de la revista

Si ya tiene sus datos de acceso, clique aquí.

Si olvidó su clave de acceso puede recuperarla clicando aquí y seleccionando la opción "He olvidado mi contraseña".

Suscribirse a:

Gastroenterología y Hepatología

Más información

Comprar

Comprar acceso al artículo

Comprando el artículo el PDF del mismo podrá ser descargado

Precio 19,34 €

Comprar ahora

Contactar

Teléfono para suscripciones e incidencias

De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h

Llamadas desde España

932 415 960

Llamadas desde fuera de España

+34 932 415 960

E-mail

atencionalcliente@elsevier.com

Publique en

Gastroenterología y Hepatología

Herramientas

Artículos
recomendados

Monitorización terapéutica de los fármacos biológicos...

Gastroenterol Hepatol. 2024;47:522-52

Comparative effectiveness and drug survival of biosimilar...

Gastroenterol Hepatol. 2024;47:553-61

Impact of proactive of infliximab monitoring using the...

Gastroenterol Hepatol. 2023;46:504-11

Artículos de acceso gratuito

Artificial intelligence-assisted identification and...

10.1016/j.gastrohep.2024.502...

Gastroenterología y Hepatología sigue las recomendaciones para la preparación, presentación y publicación de trabajos académicos en revistas biomédicas

Indexada en:

Síguenos:

Suscribirse:

Artículo

Indexada en:

Síguenos:

Suscribirse:

Artículo

Suscríbase a la newsletter